Emergent BioSolutions Inc. (EBS) - Financial and Strategic SWOT Analysis Review

GlobalData, March 2013, Pages: 48

Summary

Emergent BioSolutions Inc. (Emergent) is a biopharmaceutical company. The company operates through two divisions, namely, Biodefense and Biosciences. The company’s Biodefense division is directed to government-sponsored development and supply of countermeasures against potential agents of bioterror or biowarfare and targets the infectious disease anthrax. Emergent’s marketed product, BioThrax is the only vaccine approved by the FDA for the prevention of anthrax disease. The Biosciences division is directed to commercial opportunities and targets oncology indications.

Emergent BioSolutions Inc. Key Recent Developments

Mar 07, 2013: Emergent BioSolutions Reports Revenue Of $281.9m In 2012
Nov 19, 2012: Emergent BioSolutions Names Robert Kramer As CFO
Nov 01, 2012: Emergent BioSolutions Announces Growth Plan Through 2015
Nov 01, 2012: Emergent BioSolutions Reports Revenue Of $66.6m In Q3 2012
Oct 11, 2012: Emergent BioSolutions Selects Qumas Compliance Platform To Manage Quality Across Organization

This comprehensive SWOT profile of Emergent BioSolutions Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

List of Tables
List of Figures
Section 1 - About the Company
Emergent BioSolutions Inc. - Key Facts
Emergent BioSolutions Inc. - Key Employees
Emergent BioSolutions Inc. - Key Employee Biographies
Emergent BioSolutions Inc. - Major Products and Services
Emergent BioSolutions Inc. - Pharmaceutical Pipeline Products Data
Emergent BioSolutions Inc., Pipeline Products by Therapy Area
Emergent BioSolutions Inc., Pipeline Products by Development Phase
Emergent BioSolutions Inc. - History
Emergent BioSolutions Inc. - Company Statement
Emergent BioSolutions Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Emergent BioSolutions Inc. - Business Description
Emergent BioSolutions Inc. - Corporate Strategy
Emergent BioSolutions Inc. - SWOT Analysis
SWOT Analysis - Overview
Emergent BioSolutions Inc. - Strengths
Strength - Platform Technologies
Strength - BioThrax: Growing Market Acceptance
Strength - Strong In-House Research Activities
Emergent BioSolutions Inc. - Weaknesses
Weakness - Dependence on Third Parties
Weakness - Dependence on the US Government Contracts
Emergent BioSolutions Inc. - Opportunities
Opportunity - Increasing Awareness for Vaccines
Opportunity - ‘Fast Track’ Designation
Opportunity - Orphan Drug Designation
Opportunity - Growth Initiatives
Emergent BioSolutions Inc. - Threats
Threat - Cost Containment Pressures
Threat - Stringent Government Regulations
Threat - Increasing Competitive Pressures
Emergent BioSolutions Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Emergent BioSolutions Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Emergent BioSolutions Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Emergent BioSolutions Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Emergent BioSolutions Inc., Recent Developments
Mar 07, 2013: Emergent BioSolutions Reports Revenue Of $281.9m In 2012
Nov 19, 2012: Emergent BioSolutions Names Robert Kramer As CFO
Nov 01, 2012: Emergent BioSolutions Announces Growth Plan Through 2015
Nov 01, 2012: Emergent BioSolutions Reports Revenue Of $66.6m In Q3 2012
Oct 11, 2012: Emergent BioSolutions Selects Qumas Compliance Platform To Manage Quality Across Organization
Aug 02, 2012: Emergent BioSolutions Reports Revenue Of $70.4m In Q2 2012
Jun 18, 2012: HHS Creates New Centers To Develop, Manufacture Medical Countermeasures
Jun 18, 2012: BARDA And Emergent BioSolutions Partner To Establish Center For Innovation In Advanced Development And Manufacturing
May 03, 2012: Emergent BioSolutions Reports Revenue Of $50.3m In Q1 2012
Mar 08, 2012: Emergent BioSolutions Reports Revenue Of $107.9m In Q4 2011
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Emergent BioSolutions Inc., Key Facts
Emergent BioSolutions Inc., Key Employees
Emergent BioSolutions Inc., Key Employee Biographies
Emergent BioSolutions Inc., Major Products and Services
Emergent BioSolutions Inc., Number of Pipeline Products by Therapy Area
Emergent BioSolutions Inc., Number of Pipeline Products by Development Stage
Emergent BioSolutions Inc., Pipeline Products By Therapy Area and Development Phase
Emergent BioSolutions Inc., History
Emergent BioSolutions Inc., Other Locations
Emergent BioSolutions Inc., Subsidiaries
Emergent BioSolutions Inc., Key Competitors
Emergent BioSolutions Inc., Ratios based on current share price
Emergent BioSolutions Inc., Annual Ratios
Emergent BioSolutions Inc., Interim Ratios
Emergent BioSolutions Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Emergent BioSolutions Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Emergent BioSolutions Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Emergent BioSolutions Inc., Pipeline Products by Therapy Area
Emergent BioSolutions Inc., Pipeline Products by Development Phase
Emergent BioSolutions Inc., Performance Chart (2007 - 2011)
Emergent BioSolutions Inc., Ratio Charts
Emergent BioSolutions Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Emergent BioSolutions Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013

Soligenix, Inc.
PharmAthene, Inc.
Bavarian Nordic A/S
Elusys Therapeutics, Inc.
DynPort Vaccine Company LLC
Crucell N.V.
Merck & Co., Inc.
Human Genome Sciences, Inc.
GlaxoSmithKline plc
Cangene Corporation

Customers who bought this item also bought

• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Aerospace and Defense Industry - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Private Tutoring - Global Strategic Business Report
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020